Home
Storia in 1 fonti
GSK’s first lung cancer approval, a new IPO path and more
This week on “The Top Line,” Fierce Healthcare and Life Sciences’ editor-in-chief steps behind the microphone for a solo episode highlighting several of the biggest stories in biopharma. | This week on “The Top Line”: GSK’s lung cancer approval, an unusual IPO strategy and a push to update animal testing rules.
Raccontata da
fiercepharma.com
Timeline cronologica
- ·
GSK secures first lung cancer approval as FDA clears Jideytro in quick payoff from Nuvalent deal
In a landmark moment for its oncology ambitions, GSK has
- ·
Scaling AI in healthcare & life sciences
AI is moving beyond experimentation in healthcare and life sciences. This free whitepaper explores how leading organizations are overcoming regulatory challenges, scaling…
- ·
GSK’s first lung cancer approval, a new IPO path and more
This week on “The Top Line,” Fierce Healthcare and Life Sciences’ editor-in-chief steps behind the microphone for a solo episode highlighting several of the biggest stories in…